RA CAPITAL MANAGEMENT LLC 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:30 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA CAPITAL MANAGEMENT LLC | 4,564,867 9.900% |
-533,344 (-10.46%) |
Filing |
| 2024-11-15 5:05 pm Sale |
2024-11-13 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA CAPITAL MANAGEMENT LLC | 5,098,211 11.000% |
-103,934 (-2.00%) |
Filing |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA CAPITAL MANAGEMENT LLC | 5,202,145 9.990% |
1,038,934 (+24.96%) |
Filing |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA CAPITAL MANAGEMENT LLC | 4,163,211 9.700% |
1,373,490 (+49.23%) |
Filing |
| 2023-06-05 4:31 pm Purchase |
2023-05-25 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA CAPITAL MANAGEMENT LLC | 2,789,721 6.700% |
2,789,721 (New Position) |
Filing |